Aromatase inhibitors for male infertility.

Abstract

Some men with severely defective sperm production commonly have excess aromatase activity, reflected by low serum testosterone and relatively elevated estradiol levels. Aromatase inhibitors can increase endogenous testosterone production and serum testosterone levels. Treatment of infertile males with the aromatase inhibitors testolactone, anastrazole, and letrozole has been associated with increased sperm production and return of sperm to the ejaculate in men with non-obstructive azoospermia. Use of the aromatase inhibitors anastrazole (1 mg/day) and letrozole (2.5 mg/day) represent off-label use of these agents for impaired spermatogenesis in men with excess aromatase activity (abnormal testosterone/estradiol [T/E] ratios). Side effects have rarely been reported. Randomized controlled trials are needed to define the magnitude of benefit of aromatase inhibitor treatment for infertile men.

• Authors: Peter N Schlegel
• Journal: Fertility and sterility (Fertil Steril) Vol. 98 Issue 6 Pg. 1359-62 (Dec 2012) ISSN: 1556-5653 [Electronic] United States
• PMID: 23103016 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Chemical References

• Aromatase Inhibitors

Topics

• Aromatase Inhibitors (therapeutic use)
• Evidence-Based Medicine
• Humans
• Infertility, Male (drug therapy, epidemiology, prevention & control)
• Male
• Prevalence
• Risk Factors
• Treatment Outcome